Article | September 29, 2022

Non-Alcoholic Steatohepatitis (NASH): Asia Pacific Clinical Trial Landscape

Source: Novotech
GettyImages-1385972198 liver

NAFLD (non-alcoholic fatty liver disease) is the most common chronic liver disease in the world, affecting 25% of adults. The condition is heterogeneous and complicated, with a wide range of clinical symptoms that can be influenced by hereditary and environmental factors. NAFLD, defined by the presence of fat build-up (steatosis) in >5% of hepatocytes is divided into two types based on histologic findings: non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH). Both NAFL and NASH cause hepatic steatosis, but NASH is distinguished by inflammation and hepatocyte damage (ballooning) with or without fibrosis, which raises the risk of cirrhosis, hepatocellular carcinoma, and end-stage liver disease. It is therefore a cause of higher morbidity and mortality. Up to 20% of cases of NASH may progress to cirrhosis. [1,2]


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader